Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Nov 14, 2022 · 10-Q · 45 days after period end · 0000950170-22-024666
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$4.93M | $981.00K | -$6.15M | -$21.16M |
| EPS Diluted | -$0.11 | -$0.03 | -$0.52 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end
